hutch-med.com (HCM): Prakiraan wutah bathi resik saben saham kanggo taun ngarep

HUTCHMED (China) Limited (HCM) is monetizing its global oncology portfolio, generating multi-year royalties from patents. Tracking the projected change in earnings per share for the coming year on GURU.Markets, we note that the current metric is 27.50. Collaborations with biopharma behemoths to mitigate risks ensure stability. However, threats of approval delays in the US and an active burn of operating capital remain.
Rincian metrik lan analitis perusahaan HUTCHMED Ltd (HCM)

HUTCHMED (China) Limited's status as an oncology innovator enables the company to scale revenue through international drug recognition, which directly impacts the calculation of expected earnings per share. This metric measures the analysts' consensus forecast for net income growth rates, reflecting cash flow stability and asset revaluation risks, as clearly demonstrated by the projected change in earnings per share for the coming year.